Osimertinib plus Ramucirumab: The Best of Both Worlds?
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-4026
Abstract: Both osimertinib and the combination of erlotinib plus ramucirumab are approved for initial therapy of advanced EGFR mutation–positive non–small cell lung cancer. Osimertinib is also approved in previously treated T790M mutation–positive patients. The accompanying article… read more here.
Keywords: plus ramucirumab; osimertinib plus; ramucirumab best; best worlds ... See more keywords